A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS

Tumour-associated KRAS mutations are the most prevalent in the three RAS-family isoforms and involve many different amino-acids. Therefore, molecules able to interfere with mutant KRAS protein are potentially important for wide-ranging tumour therapy. We describe the engineering of two RAS degraders...

Descripción completa

Detalles Bibliográficos
Autores principales: Bery, Nicolas, Miller, Ami, Rabbitts, Terry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319959/
https://www.ncbi.nlm.nih.gov/pubmed/32591521
http://dx.doi.org/10.1038/s41467-020-17022-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319959/
https://www.ncbi.nlm.nih.gov/pubmed/32591521
http://dx.doi.org/10.1038/s41467-020-17022-w

Ejemplares similares